This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Govorkova, E. A. Articles by Webster, R. G. Search for Related Content PubMed PubMed Citation Articles by Govorkova, E. A. Articles by Webster, R. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2004, p. 4855-4863, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4855-4863.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Neuraminidase Inhibitor-Rimantadine Combinations Exert Additive and Synergistic Anti-Influenza Virus Effects in MDCK Cells

Department of Infectious Diseases, St. Jude Children's Research Hospital,¹ Department of Pathology, University of Tennessee, Memphis, Tennessee,⁴ Division of Biostatistics, University of Maryland Greenebaum Cancer Center, Baltimore, Maryland,³ The D. I. Ivanovsky Institute of Virology, Moscow, Russia²

Received 20 January 2004/ Returned for modification 13 June 2004/ Accepted 9 August 2004

There is insufficient information about combination therapy with approved anti-influenza agents. We tested combinations that paired a neuraminidase (NA) inhibitor (zanamivir, oseltamivir carboxylate, or peramivir) with rimantadine against infection of MDCK cells with H1N1 and H3N2 subtypes of influenza A virus and characterized their mode of interaction. When reduction of extracellular virus was analyzed by individual regression models and three-dimensional representations of the data, all three combinations showed additive and synergistic effects with no cytotoxicity. Maximum synergy against A/New Caledonia/20/99 (H1N1) virus infection was observed with <2.5 µM rimantadine paired with low concentrations of NA inhibitors. All combinations reduced the extracellular yield of A/Panama/2007/99 (H3N2) influenza virus synergistically. However, our findings were different for the cell-associated virus yield. At some drug concentrations, the yield of cell-associated virus was inhibited antagonistically. Therefore, the method of analysis can be a crucial factor in evaluating the interactions of drugs with different mechanisms. We hypothesize that assays based on cell-associated virus yield may underestimate the efficacies of drug combinations that include an NA inhibitor. Taken together, our results suggest that regimens that combine NA inhibitors and rimantadine exert synergistic anti-influenza effects in vitro. These findings provide baseline information for therapeutic testing of the drug combinations in vivo.

This article has been cited by other articles:

• Gaudreault, E., Gosselin, J. (2008). Leukotriene B4 Induces Release of Antimicrobial Peptides in Lungs of Virally Infected Mice. J. Immunol. 180: 6211-6221 [Abstract] [Full Text]  
• Tsiodras, S., Mooney, J. D, Hatzakis, A. (2007). Role of combination antiviral therapy in pandemic influenza and stockpiling implications. BMJ 334: 293-294 [Full Text]  
• Wei, L., Sandbulte, M. R., Thomas, P. G., Webby, R. J., Homayouni, R., Pfeffer, L. M. (2006). NF{kappa}B Negatively Regulates Interferon-induced Gene Expression and Anti-influenza Activity. J. Biol. Chem. 281: 11678-11684 [Abstract] [Full Text]  
• Wong, S. S. Y., Yuen, K.-y. (2006). Avian Influenza Virus Infections in Humans. Chest 129: 156-168 [Abstract] [Full Text]